AzTrials
AzTrials

SurgeryEMUsNCT06565559

EMUs: Enhanced Monitoring Using Sensors After Surgery

An observational study of Surgery and Inpatients, run by University of Edinburgh at 17 sites in 8 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

Patients can become critically unwell following surgical operations. Delay in recognition of this deterioration can result in patient harm and even death. Wearable wireless sensors that record patients vital signs such as heart rate could help improve recognition of patient deterioration. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Surgery, Inpatients
What is being tested?
Wearable Wireless Sensor
Type of treatment
Medical device
How many people
1,332 participants
Where
17 sitesin 8 countries
Study dates
28 Feb 2024to 31 Jul 2027
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study population are all patients undergoing a surgical procedure at the NIHR Global Health Research Unit on Global Surgery hubs/spoke hospitals in India, Nigeria, Ghana, Guatemala, Mexico, Rwanda, Benin and the United Kingdom that fit the eligibility criteria.

Participant Inclusion Criteria:

  • Adults 18 years and older.
  • Undergoing an elective or emergency major surgery procedure with a planned skin incision of 5 cm or greater. Any indication for surgery can exist, including benign, malignant, and trauma.
  • Willing and able to provide written informed consent.

Participant Exclusion Criteria:

  • Those under the age of 18.
  • A documented or suspected allergy to adhesive dressings.
  • Obstetric patients
  • Unwilling or unable to provide written informed consent.

Trial locations and contacts

17 sites in 8 countries. Contact the study team or a site near you to ask about taking part.

17 sites in 8 countries

Benin4 sites, 4 recruiting
  • Centre Hospitalier Universitaire Mere Enfant Lagune

    Cotonou, Littoral Department

    Ismail Lawani, ismaillawani@gmail.com

    Recruiting
  • Hopital de Zone Atlantique Ouidah

    Ouidah, Atlantique Department

    Ismail Lawani, ismaillawani@gmail.com

    Recruiting
  • Centre Hospitalier Universitaire Departemental Borgou-Alibori

    Parakou, Borgou Department

    Ismail Lawani, ismaillawani@gmail.com

    Recruiting
  • Centre Hospitalier Universitaire et Departemental Oueme Plateau

    Porto-Novo, Oeume

    Ismail Lawani, ismaillawani@gmail.com

    Recruiting

Other trials in Benin

Ghana3 sites, 3 recruiting
  • Berekum Holy Family Hospital

    Berekum, Berekum East

    Stephen Tabiri, kstephenba@yahoo.com

    Recruiting
  • Tamale Teaching Hospital

    Tamale

    Stephen Tabiri, kstephenba@yahoo.com

    Recruiting
  • Techiman Holy Family Hospital

    Techiman, Bono East

    Stephen Tabiri, kstephenba@yahoo.com

    Recruiting

Other trials in Ghana

India3 sites, 3 recruiting
  • Christian Medical College and Hospital

    Ludhiana, Punjab

    Dhruv Ghosh, dhruvghosh@cmcludhiana.in

    Recruiting
  • Lady Willingdon Hospital

    Manali, Himachal Pradesh

    Dhruv Ghosh, dhruvghosh@cmcludhiana.in

    Recruiting
  • Padhar Hospital

    Pādhar, Madhya Pradesh

    Dhruv Ghosh, dhruvghosh@cmcludhiana.in

    Recruiting

Other trials in India

Nigeria3 sites, 3 recruiting
  • Obafemi Awolowo University Teaching Hospital Complex

    Ife

    Adesoji Ademuyiwa, adesojiademuyiwa@yahoo.co.uk

    Not yet recruiting
  • Lagos State University Teaching Hospital

    Ikeja

    Adesoji Ademuyiwa, adesojiademuyiwa@yahoo.co.uk

    Not yet recruiting
  • Lagos University Teaching Hospital

    Lagos

    Adesoji Ademuyiwa, adesojiademuyiwa@yahoo.co.uk

    Recruiting

Other trials in Nigeria

Guatemala1 site, 1 recruiting
  • Hospital General San Juan de Dios

    Guatemala City

    Maria Lorena Aguilera Arévalo, cuevaslore@ufm.edu

    Recruiting

Other trials in Guatemala

Mexico1 site, 1 recruiting
  • Hospital Español de Veracruz

    Veracruz

    Antonio Ramos de la Medina, ramos.antonio@heveracruz.mx

    Recruiting

Other trials in Mexico

Rwanda1 site, 1 recruiting
  • University Teaching Hospital of Rwanda

    Kigali

    Faustin Ntirenganya, fostino21@yahoo.fr

    Not yet recruiting

Other trials in Rwanda

United Kingdom1 site
  • Royal Infirmary of Edinburgh

    Edinburgh, EH16 4SA

    Active, not recruiting

Other trials in United Kingdom

About this study

Patients can become critically unwell following surgical operations. Delay in recognition of this deterioration can result in patient harm and even death. Wearable wireless sensors that record patients vital signs such as heart rate could help improve recognition of patient deterioration. The goal of this observational study: Enhanced Monitoring Using Sensors After Surgery (EMUs) is to determine if data from wearable physiological monitors can be used for the early detection of postoperative deterioration, while being acceptable to patients and healthcare staff. The study participants and surgical inpatients undergoing open surgery. There are 3 objectives which each represent a stage of the study:

  1. To perform usability testing of device with clinicians, nurses, and healthcare workers in non-clinical environment.
  2. To determine baseline postoperative monitoring practice across our network and perform device usability testing in clinical environment.
  3. To perform a shadow-mode cohort study with collection of time-stamped sensor clinical event data to determine relationships between physiological waveforms and patient deterioration.
Read more

This registration focuses on the shadow-mode cohort study.

Participants will wear wireless sensors on their chest and fingers, pre-, intra-, and post-operatively for up to 10 days. The sensors will record their vital signs such as heart rate, and oxygen levels. This will then be analysed, and used to aid the design of early detection algorithms that may be able to predict clinical illness or complications in this patient group. This is an observational study gathering real time data only. No changes in patient care will result, and in Stages 2 and 3 no sensor data will be available to clinical teams. This study will be performed in departments of general surgery in Benin, Ghana, Guatemala, India, Mexico, Nigeria, Rwanda, and the United Kingdom.

Read the detailed description

Patients who die after surgery frequently have treatable complications which are not identified in a timely manner. This is due to a failure to "recognize", "relay" or "react" to the deterioration of a patient in the postoperative period. This study aims to determine whether data from wearable physiological monitors can be used for the early detection of patient deterioration, while being acceptable to patients and healthcare staff. If found useful, future studies would be conducted to determine the performance and safety of such a device.

This study has three objectives which will be addressed in three stages.

STAGE 1. Usability testing of device with clinicians, nurses, and healthcare workers in non-clinical environment.

STAGE 2. Baseline postoperative monitoring practice assessment and device usability testing in clinical environment.

STAGE 3. Shadow-mode cohort study with collection of time-stamped sensor and clinical event data to determine relationships between physiological waveforms and patient deterioration.

This registration focuses on the shadow-mode cohort study.

This study will be performed in departments of general surgery in Benin, Ghana, Guatemala, India, Mexico, Nigeria, Rwanda, and the UK. In Stages 2 and 3, patients will have undergone major surgery and will be recovering in postoperative wards.

This study can be performed using any suitable wearable device (it is device agnostic), as it seeks to gather generalisable information. In the first instance, the Sibel ANNE® One device will be used. ANNE® One is a wireless ICU-grade dual sensor system that provides real-time physiological monitoring. The system features two skin-mounted, bio-integrated sensors that provide continuous storage of vital sign measurements and physiological waveforms.

This is an observational study gathering real time data only. No changes in patient care will result, and in Stages 2 and 3 no sensor data will be available to clinical teams. True equipoise exists: it is not clear whether these data are useful or how they should be used. Patients will be managed with standard care throughout.

Wearable sensors have potential application in improving postoperative monitoring and consequently, the reduction of avoidable morbidity and mortality. Sensor data may be used to generate prediction algorithms providing a continuous readout of individual patient risk. Such algorithms could enhance healthcare workers' capacity to identify and intervene upon patients with early complications. However, few high-quality studies have yet been performed in this area.

This study has approvals form the following ethical review boards:

Edinburgh Medical School Research Ethics Committee West of Scotland Research Ethics Service (on behalf of NHS Health Research Authority) Health and Care Research Wales (on behalf of NHS Health Research Authority) Ghana Health Service Ethics Review Committee Comite de Investigacion, Hospital General San Juan de Dios, Guatemala, Guatemala Christian Medical College and Hospital, Institutional Ethics Committee, Ludhiana, India El Comite de Etica en Investigacion del Hospital General de Boca del Rio, Veracruz, Mexico Lagos University Teaching Hospital Health Research Ethics Committee, Lagos Nigeria Lagos State University Teaching Hospital Health Research Ethics Committee, Ikeja, Nigeria Obafemi Awolowo University Hospitals Teaching Complex, Ethics and Research Committee, Ife, Nigeria Ethics Committee of University Teaching Hospital of Kigali, Kigali, Rwanda

Conditions
Surgery, Inpatients
Being tested
Wearable Wireless Sensor
Keywords
Surgery, Wearable Devices, Global Surgery

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Wearable Wireless SensorDevice

    Stage III is a shadow mode evaluation of the device with participants wearing sensors pre-, intra-, and post-operatively. Sensor and clinical data will be collected contemporaneously in the clinical environment. No sensor data is made available to clinical teams for decision making, with no change in patient care.

Study groups in NCT06565559
Study groupRoleWhat they receive
Study CohortAll surgical patients that fit the study eligibility criteria.
Receives: Device: Wearable Wireless Sensor

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cardiovascular data from wearable device

    Data includes core vital sign measures to assess the patient's cardiovascular function (e.g. heart rate in beats per minute), advanced indices (e.g., pulse arrival time, Heart Rate (HR) /Respiratory Rate (RR) quotient) and raw waveform data.

    Measured: 0-10 days from device application.

  2. Respiratory data from wearable device

    Data includes core vital sign measures to assess the patient's respiratory function (e.g. oxygen saturation as a percentage), advanced indices (e.g, Heart Rate (HR) /Respiratory Rate (RR) quotient) and raw waveform data.

    Measured: 0-10 days from device application.

  3. Body temperature data from wearable device

    Data includes core vital sign measures (e.g. temperature measurement in degrees centigrade), advanced indices, and raw waveform data.

    Measured: 0-10 days from device application.

Secondary outcomes (8)
  1. Standard-of-care cardiovascular vital sign observation data

    Standard-of-care vital sign observation data to assess cardiovascular function e.g. heart rate in beats per minute, blood pressure in mmHg at a frequency normally collected. These will be assessed as part of the National Early Warning Score 2 system (NEWS2) which a validated early warning score for detecting patient deterioration or equivalent in participating centers.

    Measured: 0-10 days from day of device application.

  2. Standard-of-care respiratory vital sign observation data

    Standard-of-care vital sign observation data to assess respiratory function e.g. respiratory rate in breaths per minute, oxygen saturations in percentage, at a frequency normally collected. These will be assessed as part of the National Early Warning Score 2 system (NEWS2) which a validated early warning score for detecting patient deterioration, or equivalent in participating centers.

    Measured: 0-10 days from day of device application.

  3. Standard-of-care temperature vital sign observation data

    Standard-of-care vital sign observation data to assess temperature e.g. in degrees centigrade or Fahrenheit, at a frequency normally collected. These will be assessed as part of the National Early Warning Score 2 system (NEWS2) which a validated early warning score for detecting patient deterioration or equivalent in participating centers.

    Measured: 0-10 days from day of device application.

  4. Standard-of-care neurological observation data

    Standard-of-care vital sign observation data to assess neurological function e.g. Alert Verbal Pain Unresponsive (AVPU) at a frequency normally collected. These will be assessed as part of the National Early Warning Score 2 system (NEWS2) which a validated early warning score for detecting patient deterioration or equivalent in participating centres.

    Measured: 0-10 days from day of device application.

  5. Incidence of clinical complications during the study period

    Incidence of clinical diagnosis data such as bleeding, major adverse cardiac event, sepsis will be derived from patient records and recorded and any uncertainty reviewed post hoc by an expert adjudication panel. Clinical complication data will also be gathered at 30 days.

    Measured: 0-10 days from the day of device application and then 30 day follow up will be performed.

  6. Incidence of clinical investigations during the study period

    The incidence of clinical investigations and descriptive details about the investigations will be derived from the patient records such as chest xray, CT abdomen, and wound swab.

    Measured: 0-10 days from the day of device application.

  7. Incidence of clinical interventions during the study period

    The incidence of clinical interventions performed and descriptive details, during the period of the device being worn will be recorded, e.g. commencement of antibiotics, unplanned admission to critical care, unplanned reoperation.

    Measured: 0-10 days from the day of device application.

  8. Incidence and results of blood tests to assess patient physiological status during the study period

    The incidence of blood tests will be recorded and the associated results from during the 10 day study period. Bloods tests recorded will include full blood count, urea and electrolytes, inflammatory markers, liver function tests and coagulation profile as well as blood gas results. They will be recorded using whichever the standard units are at participating centres.

    Measured: 0-10 days from the day of device application.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Aug 2024
  2. Study start28 Feb 2024
  3. Primary completion31 Jul 2027 (estimated)
  4. Study completion31 Jul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,332 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06565559
Sponsor's protocol ID
EMUs
Other IDs
13344828
Acronym
EMUs
Status last verified
Feb 2026
First submitted
15 Jul 2024
Last updated
10 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes

Publications

  • Burke JR, Downey C, Almoudaris AM. Failure to Rescue Deteriorating Patients: A Systematic Review of Root Causes and Improvement Strategies. J Patient Saf. 2022 Jan 1;18(1):e140-e155. doi: 10.1097/PTS.0000000000000720.

    PubMed 32453105
  • Ghaferi AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated with inpatient surgery. N Engl J Med. 2009 Oct 1;361(14):1368-75. doi: 10.1056/NEJMsa0903048.

    PubMed 19797283
  • Jiwa A, Cameron MM, Ademuyiwa AO, Adisa A, Aguilera Arevalo ML, Bahrami Hessari M, Bhangu A, Brennan PM, Clark N, Cresswell K, Czerwinska I, D'Adderio L, Gunn E, Haque PD, Ikegwuonu T, Lawani I, Morton D, Nganwa A, Ntirenganya F, Pius R, Ramos de la Medina A, Samuel S, Shaw CA, Tabiri S, Townsend RC, Varghese C, Ghosh D, Harrison EM; NIHR Global Health Research Unit on Global Surgery. Continuous physiological monitoring for the detection of postoperative deterioration: a protocol for a multistage, multicentre, international, prospective cohort study. BMJ Open. 2025 Oct 6;15(10):e104463. doi: 10.1136/bmjopen-2025-104463.

    PubMed 41057181

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in